HOW STRONG IS THE CASE FOR INTENSIVE CANCER CHEMOTHERAPY?
- 31 October 1976
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 308 (7994) , 1071-1072
- https://doi.org/10.1016/s0140-6736(76)90979-x
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Burkitt's lymphoma in Ibadan: Response to various doses of cyclophosphamide and long-term survivorsPublished by Elsevier ,1976
- Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemiaBritish Journal of Cancer, 1975
- Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamideGynecologic Oncology, 1974
- Amputation and Adriamycin in Primary OsteosarcomaNew England Journal of Medicine, 1974
- Single-drug therapy in ovarian cancer: Factors influencing responseGynecologic Oncology, 1973
- Chemotherapy of acute lymphocytic leukemia of childhoodCancer, 1972
- Recent advances in the chemotherapy of metastatic osteogenic sarcomaCancer, 1972
- Eradication Of Leukaemic Cells (L1210) by Methotrexate and Methotrexate Plus Citrovorum FactorNature, 1966
- Progress and Perspectives in the Chemotherapy of Acute LeukemiaPublished by Elsevier ,1965
- High-dose Mustine Therapy for Bronchial CarcinomaBMJ, 1963